Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Oncotarget - 15 Nov 2016

Toomey Sinead, Madden Stephen F, Furney Simon J, Fan Yue, McCormack Mark, Stapleton Carragh, Cremona Mattia, Cavalleri Gianpiero L, Milewska Malgorzata, Elster Naomi, Carr Aoife, Fay Joanna, Kay Elaine W, Kennedy Susan, Crown John, Gallagher William M, Hennessy Bryan T, Eustace Alex J

Abstract excerpt

BACKGROUND: Trastuzumab treatment for women with HER2-positive breast cancer (BC) resulted in the significant improvement of both relapse free survival (RFS) and overall survival (OS). However, many women who are classified as HER2-positive do not respond. Many studies have focused on the role of somatic mutations rather than germline polymorphisms in trastuzumab resistance. RESULTS: We completed an Agena...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to Germ-Line Mutation

Share to Proportional Hazards Models

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 27776352
DOI: 10.18632/oncotarget.12782
PMCID: PMC5342757

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.PMID 27776352Read ↗

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.Semantic proximity Read ↗

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.Semantic proximity Read ↗

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.Semantic proximity Read ↗

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.Semantic proximity Read ↗

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Semantic proximity Read ↗

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast CancerSemantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trialSemantic proximity Read ↗

A genome-wide association study of prognosis in breast cancer.Semantic proximity Read ↗

Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.Semantic proximity Read ↗

HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.Semantic proximity Read ↗

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.